A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma

Inclusion Criteria: Indolent B cell Non-Hodgkin's lymphoma patients with prior therapy who satisfy the conditions listed below. No restrictions regarding gender. * Patients with histologically or cytologically confirmed indolent B cell Non-Hodgkin's lymphoma. * Patients who had not received treatment (chemotherapy, antibody therapy and radiation/ radiotherapy) for more than 4 weeks following prior therapy and who are judged to carry no effect from the prior therapy. * Patients aged from 20 to less than 75 years. * Patients who had agreed in-patient during first course therapy. * Patients from whom written consent to participate in this study has been obtained. Exclusion Criteria:Patients who meet any of the following criteria will be excluded. * Patients with apparent infections. * Patients with serious complications (hepatic failure or renal failure). * Patients with complication or history of serious heart failure (e.g. cardiac infarction, ischemic heart disease). * Patients with serious digestive symptoms (nausea/ vomiting/ diarrhea). * Patients who are known to be positive for HBV, HCV or HIC. * Patients receiving other investigational drugs within 3 months before registration in the study. * Patients with allogenic transplant. * Women who are pregnant, of childbearing potential, or lactating. * Patients who do not agree to contraception. * Otherwise, patients who are judged by the investigator as being unsuitable for inclusion in the study.